David S Moura

19PUBLICATIONS
75CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersSolid tumoursRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Mar 12, 2026
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma.

Javier Martin-Broto, Javier Martinez-Trufero, Roberto Diaz-Beveridge

|Jan 15, 2026
Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma.

David S Moura, Jesus Lopez-Marti, Hussein Tawbi

|Oct 02, 2024
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).

Javier Martin-Broto, Roberto Diaz-Beveridge, David Moura

|Sep 16, 2024
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial.

David S Moura, Jesus M Lopez-Marti, Iva Benesova

|May 17, 2024
HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.

David S Moura, Jose L Mondaza-Hernandez, Paloma Sanchez-Bustos

|Mar 27, 2024
Best Overall Response-Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE.

Jiangang Liu, David S Moura, Robin L Jones

Pageof 4

Frequent Collaborators

16 joint publications

Javier Martin-Broto

11 joint publications

Nadia Hindi

6 joint publications

Jose L Mondaza-Hernandez

5 joint publications

Antonio Gutierrez